AG-236 (ALN-TMP) Investigational RNAi therapy licensed to Agios, undergoing Phase 1 development for polycythemia vera, a disorder characterized by excess red blood cells.
Visit productCosigns Received
Be the first Cosign
Put your name behind AG-236 (ALN-TMP).
Add it to your Products I use list and share why you use it.